{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:45Z","timestamp":1740167745050,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"BlueClinical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40290-023-00479-7","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T06:02:27Z","timestamp":1685426547000},"page":"319-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpersonal Values of Patients Participating in Phase II\u2013III Clinical Trials: Implications for Clinical Trial Representativeness"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6073-2922","authenticated-orcid":false,"given":"Rita","family":"Gouveia","sequence":"first","affiliation":[]},{"given":"Vitor Tedim","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Ant\u00e3o","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Almeida","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"2","key":"479_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1513\/pats.200701-009GC","volume":"4","author":"Z Mosenifar","year":"2007","unstructured":"Mosenifar Z. Population issues in clinical trials. Proc Am Thorac Soc. 2007;4(2):185\u20138.","journal-title":"Proc Am Thorac Soc"},{"key":"479_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1467-6494.2005.00335.x","volume":"73","author":"B Marcus","year":"2005","unstructured":"Marcus B, Schuetz A. Who are the people reluctant to participate in research? Personality correlates of four different types of nonresponse as inferred from self- and observer ratings. J Pers. 2005;73:959\u201384.","journal-title":"J Pers"},{"issue":"1","key":"479_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mehy.2005.01.018","volume":"65","author":"CL Tishler","year":"2005","unstructured":"Tishler CL, Bartholomae S, Rhodes AR. Personality profiles of normal healthy research volunteers: a potential concern for clinical drug trial investigators? Med Hypotheses. 2005;65(1):1\u20137.","journal-title":"Med Hypotheses"},{"issue":"4","key":"479_CR4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/bimj.201600084","volume":"59","author":"M Ursino","year":"2017","unstructured":"Ursino M, Zohar S, Lentz F, Alberti C, Friede T, Stallard N, et al. Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. Biom J Biom Z. 2017;59(4):804\u201325.","journal-title":"Biom J Biom Z."},{"issue":"11","key":"479_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/0191-8869(89)90088-3","volume":"10","author":"J Cam\u00ed","year":"1989","unstructured":"Cam\u00ed J, Llorente M, Farr\u00e9 M, Badenas J, Ugena B. Personality of healthy volunteers participating in Phase I clinical trials. Pers Individ Differ. 1989;10(11):1199\u2013200.","journal-title":"Pers Individ Differ"},{"issue":"5","key":"479_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10865-013-9548-z","volume":"37","author":"M Jokela","year":"2014","unstructured":"Jokela M, Pulkki-R\u00e5back L, Elovainio M, Kivim\u00e4ki M. Personality traits as risk factors for stroke and coronary heart disease mortality: pooled analysis of three cohort studies. J Behav Med. 2014;37(5):881\u20139.","journal-title":"J Behav Med"},{"key":"479_CR7","doi-asserted-by":"crossref","unstructured":"Kang H, Miksche MS, Ellingsen DM. The association between personality traits and placebo effects: a preregistered systematic review and meta-analysis [Internet]. PsyArXiv; 2022 [cited 2022 Jun 4]. https:\/\/psyarxiv.com\/tc9e8\/.","DOI":"10.31234\/osf.io\/tc9e8"},{"key":"479_CR8","unstructured":"Evers AWM. Role of personality traits in reporting the development of adverse drug reactions\u202f: a prospective cohort study of the Estonian general population. [cited 2022 Jun 4]. https:\/\/core.ac.uk\/reader\/159768288."},{"issue":"6","key":"479_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1037\/1064-1297.15.6.539","volume":"15","author":"CL Tishler","year":"2007","unstructured":"Tishler CL, Apseloff G, Bartholomae S, Reiss NS, Rhodes AR, Singh A. Are normal healthy research volunteers psychologically healthy? A pilot investigation. Exp Clin Psychopharmacol. 2007;15(6):539\u201345.","journal-title":"Exp Clin Psychopharmacol."},{"issue":"7","key":"479_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5414\/CPP46340","volume":"46","author":"L Almeida","year":"2008","unstructured":"Almeida L, Falc\u00e3o A, Vaz-da-Silva M, Coelho R, Albino-Teixeira A, Soares-da-Silva P. Personality characteristics of volunteers in Phase 1 studies and likelihood of reporting adverse events. Int J Clin Pharmacol Ther. 2008;46(7):340\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"479_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2147\/PRBM.S299720","volume":"14","author":"M Czerniawska","year":"2021","unstructured":"Czerniawska M, Szyd\u0142o J. Do values relate to personality traits and if so, in what way?\u2014Analysis of relationships. Psychol Res Behav Manag. 2021;14:511\u201327.","journal-title":"Psychol Res Behav Manag"},{"key":"479_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.paid.2009.06.002","volume":"47","author":"L Parks-Leduc","year":"2009","unstructured":"Parks-Leduc L, Guay R. Pesonality, values, and motivation. Pers Individ Differ. 2009;47:675\u201384.","journal-title":"Pers Individ Differ"},{"key":"479_CR13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3389\/fpsyg.2019.00934","volume":"10","author":"V Ponizovskiy","year":"2019","unstructured":"Ponizovskiy V, Grigoryan L, K\u00fchnen U, Boehnke K. Social construction of the value-behavior relation. Front Psychol. 2019;10:934.","journal-title":"Front Psychol"},{"key":"479_CR14","first-page":"2011","volume-title":"Invent\u00e1rio de Valores Interpessoais (SIV): 2a Edi\u00e7\u00e3o Manual T\u00e9cnico","author":"LV Gordon","year":"2001","unstructured":"Gordon LV. Invent\u00e1rio de Valores Interpessoais (SIV): 2a Edi\u00e7\u00e3o Manual T\u00e9cnico. Lisbon: CEGOC-TEA Ltd; 2001. p. 2011."},{"key":"479_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF03256785","volume":"23","author":"L Almeida","year":"2009","unstructured":"Almeida L, Vaz-da-Silva M, Coelho R, Albino-Teixeira A, Soares-da-Silva P. Interpersonal values of healthy subjects who volunteer for phase I clinical trials. Pharm Med. 2009;23:299\u2013303.","journal-title":"Pharm Med."},{"key":"479_CR16","volume-title":"Manual for survey of interpersonal values","author":"LV Gordon","year":"1960","unstructured":"Gordon LV. Manual for survey of interpersonal values. Chicago: Science Research Associates Inc; 1960."},{"key":"479_CR17","volume-title":"SIV: CEGOC System, software para cota\u00e7\u00e3o informatizada do teste SIV","author":"D Rocha","year":"2001","unstructured":"Rocha D. SIV: CEGOC System, software para cota\u00e7\u00e3o informatizada do teste SIV. Lisbon: CEGOC-TEA Ltd; 2001."},{"issue":"5","key":"479_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","volume":"123","author":"CA Umscheid","year":"2011","unstructured":"Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgrad Med. 2011;123(5):194\u2013204.","journal-title":"Postgrad Med"},{"key":"479_CR19","first-page":"237","volume":"21","author":"J Jones","year":"2006","unstructured":"Jones J, Nyhof-Young J, Moric J, Friedman A, Wells W, Catton P. Identifying motivations and barriers to patient participation in clinical trials. J Cancer Educ Off J Am Assoc Cancer Educ. 2006;21:237\u201342.","journal-title":"J Cancer Educ Off J Am Assoc Cancer Educ."},{"issue":"1","key":"479_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13063-015-1105-3","volume":"17","author":"SY Moorcraft","year":"2016","unstructured":"Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, et al. Patients\u2019 willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials. 2016;17(1):17.","journal-title":"Trials"},{"issue":"10","key":"479_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1046\/j.1525-1497.1998.00204.x","volume":"13","author":"AC Kao","year":"1998","unstructured":"Kao AC, Green DC, Davis NA, Koplan JP, Cleary PD. Patients\u2019 trust in their physicians. J Gen Intern Med. 1998;13(10):681\u20136.","journal-title":"J Gen Intern Med"},{"key":"479_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1590\/1809-4503201400040004","volume":"17","author":"SM Dainesi","year":"2014","unstructured":"Dainesi SM, Goldbaum M. Reasons behind the participation in biomedical research: a brief review. Rev Bras Epidemiol. 2014;17:842\u201351.","journal-title":"Rev Bras Epidemiol"},{"issue":"1","key":"479_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1745-6215-11-31","volume":"11","author":"SK McCann","year":"2010","unstructured":"McCann SK, Campbell MK, Entwistle VA. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials. 2010;11(1):31.","journal-title":"Trials"},{"issue":"2","key":"479_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0738-3991(98)00060-3","volume":"35","author":"FW Verheggen","year":"1998","unstructured":"Verheggen FW, Nieman F, Jonkers R. Determinants of patient participation in clinical studies requiring informed consent: why patients enter a clinical trial. Patient Educ Couns. 1998;35(2):111\u201325.","journal-title":"Patient Educ Couns"},{"issue":"2","key":"479_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/picr.PICR_6_20","volume":"11","author":"M Desai","year":"2020","unstructured":"Desai M. Recruitment and retention of participants in clinical studies: critical issues and challenges. Perspect Clin Res. 2020;11(2):51\u20133.","journal-title":"Perspect Clin Res"},{"issue":"7","key":"479_CR26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s10620-006-8028-5","volume":"51","author":"M Mor","year":"2006","unstructured":"Mor M, Niv G, Niv Y. Patient retention in a clinical trial: a lesson from the rofecoxib (VIOXX) study. Dig Dis Sci. 2006;51(7):1175\u20138.","journal-title":"Dig Dis Sci"},{"key":"479_CR27","unstructured":"The Economist Intelligence Unit. The innovation imperative: the future of drug development. Part I: research methods and findings, 2018. https:\/\/druginnovation.eiu.com\/research-methodsand-findings\/. Accessed 05 Apr 2023."},{"key":"479_CR28","doi-asserted-by":"crossref","unstructured":"Bourin M. Criteria of Patient Selection in a Clinical Trial. SOJ Pharm Pharm Sci [Internet]. 2017 Jun 7 [cited 2021 Sep 23];4(3). https:\/\/symbiosisonlinepublishing.com\/pharmacy-pharmaceuticalsciences\/pharmacy-pharmaceuticalsciences64.php.","DOI":"10.15226\/2374-6866\/4\/3\/00164"},{"key":"479_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2019.109866","volume":"128","author":"A Kern","year":"2020","unstructured":"Kern A, Kramm C, Witt CM, Barth J. The influence of personality traits on the placebo\/nocebo response. J Psychosom Res. 2020;128: 109866.","journal-title":"J Psychosom Res"},{"issue":"5","key":"479_CR30","first-page":"505","volume":"27","author":"ML Kern","year":"2008","unstructured":"Kern ML, Friedman HS. Do conscientious individuals live longer? A quantitative review. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2008;27(5):505\u201312.","journal-title":"Health Psychol Off J Div Health Psychol Am Psychol Assoc."},{"issue":"1","key":"479_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.2044-8287.2011.02055.x","volume":"17","author":"E Ferguson","year":"2012","unstructured":"Ferguson E, Bibby PA. Openness to experience and all-cause mortality: a meta-analysis and requivalent from risk ratios and odds ratios. Br J Health Psychol. 2012;17(1):85\u2013102.","journal-title":"Br J Health Psychol"},{"issue":"5","key":"479_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/PSY.0000000000000070","volume":"76","author":"PTJ Costa","year":"2014","unstructured":"Costa PTJ, Weiss A, Duberstein PR, Friedman B, Siegler IC. Personality facets and all-cause mortality among medicare patients aged 66 to 102 years: a follow-on study of Weiss and Costa (2005). Psychosom Med. 2014;76(5):370\u20138.","journal-title":"Psychosom Med"},{"key":"479_CR33","doi-asserted-by":"publisher","unstructured":"Faulkner SD, Somers F, Boudes M, Nafria B, Robinson P. Using patient perspectives to inform better clinical trial design and conduct: current trends and future directions. Pharm Med [Internet]. 2023 Jan 18 [cited 2023 Apr 7]. https:\/\/doi.org\/10.1007\/s40290-022-00458-4.","DOI":"10.1007\/s40290-022-00458-4"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00479-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-023-00479-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00479-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T16:20:33Z","timestamp":1688228433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-023-00479-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1007\/s40290-023-00479-7","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"type":"print","value":"1178-2595"},{"type":"electronic","value":"1179-1993"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"18 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by BlueClinical, Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study respects the fundamental principles established in the Declaration of Helsinki of the World Medical Association, and the Convention of the Council of Europe related to human rights and biomedicine, and fulfills the requirements established in Portuguese legislation surrounding biomedical research, the protection of personal data, and bioethics. All procedures performed in this study involving human participants were in accordance with the ethical standards of the applicable institutional review board and ethics committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from each participant included in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RG, VTC, and LA were involved in the study conceptualization and design. RG, JA, and LA contributed to the analysis and interpretation of data. RG, JA, VTC, and LA contributed to the writing, reviewing, and editing of the draft and final version of the article. RG, JA VTC, and LA read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}